Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

Katia Desroziers, Samuel Aballéa, Khaled Maman, Jameel Nazir, Isaac Odeyemi, Zalmai Hakimi, Katia Desroziers, Samuel Aballéa, Khaled Maman, Jameel Nazir, Isaac Odeyemi, Zalmai Hakimi

Abstract

Background: Limited utility data on patients suffering from overactive bladder (OAB) are available in the literature. The objectives of this study were to estimate utility values in patients with OAB using the generic EQ-5D questionnaire and the OAB-5D disease specific questionnaire, to investigate the relationship between utilities and symptoms, and to evaluate the sensitivity of the two instruments to changes in symptom severity.

Methods: Analyses were based on pooled data from three large multicenter randomized 12-week placebo-controlled trials (SCORPIO, ARIES, CAPRICORN). Patients completed a micturition diary, EQ-5D and OAB-q (a quality of life questionnaire from which OAB-5D is derived) at baseline and at weeks 4, 8 and 12. Time trade-off tariffs elicited from UK population were applied to obtain utilities from both instruments. Repeated measures regressions were used to estimate EQ-5D and OAB-5D utilities by micturition frequency and incontinence severity level. As a test of sensitivity of the instruments, utility changes from baseline to week 12 were estimated by symptomatic response (improvement, stable or worsening).

Results: The sample included 4427 patients. Mean utilities (± standard deviation) across all visits were 0.82 (± 0.21) for EQ-5D and 0.86 (±0.09) for OAB-5D. Correlation between EQ-5D and OAB-5D was 0.34 (p < 0.0001). Both OAB-5D and EQ-5D utilities increased as OAB symptoms improved. Utility values were similar for severe levels of symptoms, but higher with OAB-5D than with EQ-5D for mild cases. Micturitions and incontinence had similar impact on EQ-5D utilities, but micturitions had greater impact on OAB-5D utilities than incontinence. Changes from baseline in OAB-5D utilities differed significantly according to symptomatic response. Changes in EQ-5D utilities were not significantly associated with changes in micturition frequency and weakly associated with changes in incontinence severity among patients with mild symptoms at baseline.

Conclusions: This study showed that both EQ-5D and OAB-5D can detect changes in severity of OAB, especially in severe cases. However, OAB-5D is more sensitive than EQ-5D in measuring differences between treatments in milder cases. Both OAB-5D and EQ-5D-although leading to different results-may be useful to derive utilities from clinical trial data and perform cost-effectiveness analyses.

Trial registration: Clinical Trials NCT00689104, NCT00662909, NCT00912964.

Figures

Figure 1
Figure 1
Adjusted utility estimates of EQ-5D and OAB-5D according to symptom frequency level. A–Adjusted utility estimates of EQ-5D and OAB-5D according to micturition frequency level; B–Adjusted utility estimates of EQ-5D and OAB-5D according to incontinence episode frequency level.

References

    1. Abrams P, Artibani W, Cardozo L, Dmochowski R, Van Kerrebroeck P, Sand P. International Continence Society. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009;28(4):287. doi: 10.1002/nau.20737.
    1. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6(Suppl 11):S574–S579.
    1. Irwin DE, Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314. doi: 10.1016/j.eururo.2006.09.019. discussion 1314-5.
    1. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 2008.
    1. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
    1. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology. 1997;50(Suppl 6A):100–107. discussion 108-10.
    1. Johannesson M, O’Conor RM, Kobelt-Nguyen G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol. 1997;80(4):557–562. doi: 10.1046/j.1464-410X.1997.00420.x.
    1. Yang Y, Brazier J, Tsuchiya A, Coyne K. Estimating a preference-based single index from the overactive bladder questionnaire. Value Health. 2009;12(1):159–166. doi: 10.1111/j.1524-4733.2008.00413.x.
    1. Stolk EA, Busschbach JJ. Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Qual Life Res. 2003;12(4):363–371. doi: 10.1023/A:1023453405252.
    1. Eurich DT, Johnson JA, Reid KJ, Spertus JA. Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes. 2006;4:89. doi: 10.1186/1477-7525-4-89.
    1. McKenna SP, Ratcliffe J, Meads DM, Brazier JE. Development and validation of a preference based measure derived from the Cambridge pulmonary hypertension outcome review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes. 2008;6:65. doi: 10.1186/1477-7525-6-65.
    1. Young T, Yang Y, Brazier JE, Tsuchiya A, Coyne K. The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis. Qual Life Res. 2009;18(2):253–265. doi: 10.1007/s11136-008-9428-0.
    1. Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11(6):563–574. doi: 10.1023/A:1016370925601.
    1. Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ) Neurourol Urodyn. 2005;24(3):215–225. doi: 10.1002/nau.20110.
    1. Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q) Qual Life Res. 2005;14(3):849–855. doi: 10.1007/s11136-004-0706-1.
    1. Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–295. doi: 10.1016/j.eururo.2012.10.016.
    1. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–1395. doi: 10.1016/j.juro.2012.10.017.
    1. Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stölzel M, Martin N, Gunther A, Van Kerrebroeck P. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β(3)-adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–320. doi: 10.1016/j.urology.2013.02.077.
    1. Dolan P, Jones-Lee M. The time trade-off: a note on the effect of lifetime reallocation of consumption and discounting. J Health Econ. 1997;16(6):731–739. doi: 10.1016/S0167-6296(96)00514-0.
    1. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. York Centre for Health Economics; 1999. Discussion Paper 172. .
    1. Fryback DG, Dunham NC, Palta M, Hanmer J, Buechner J, Cherepanov D, Herrington SA, Hays RD, Kaplan RM, Ganiats TG, Feeny D, Kind P. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care. 2007;45(12):1162–1170. doi: 10.1097/MLR.0b013e31814848f1.
    1. Kobelt G, Jönsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn. 1998;17(6):599–611. doi: 10.1002/(SICI)1520-6777(1998)17:6<599::AID-NAU4>;2-J.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren